Corporate ActionJul 27, 2026, 06:07 AM
VERAXA Biotech Shareholders Approve Proposals for Strategic Flexibility
AI Summary
VERAXA Biotech AG shareholders overwhelmingly approved all proposals at an Extraordinary General Meeting, granting the company enhanced corporate and financing flexibility. Key approvals include conditional share capital for options and warrants, a capital band until 2030, and an increase in the maximum Board of Directors members. Additionally, the company announced the initiation of cell line development with ATUM for its lead BiTAC®-TCE program, a crucial step towards clinical development for its next-generation cancer therapeutics.
Key Highlights
- Shareholders approved all proposals at the Extraordinary General Meeting with over 99.94% majority.
- 102,102,301 voting shares, representing 72.20% of total share capital, were represented.
- Approved conditional share capital for shareholder options and warrants.
- Implemented a capital band through December 31, 2030.
- Increased the maximum number of Board of Directors members from five to seven.
- Initiated cell line development with ATUM for its lead BiTAC®-TCE program.
- This advances the BiTAC®-TCE program towards IND/CTA-enabling activities and clinical development.
Price Impact
More from VRXA